Nebivolol is under clinical development by Betaliq and currently in Phase II for Open-Angle Glaucoma. According to GlobalData, Phase II drugs for Open-Angle Glaucoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nebivolol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nebivolol overview

Nebivolol is under development for the treatment of primary open angle glaucoma and ocular hypertension. It is administered through ophthalmic route as eye drops. It acts by targeting Beta-1 adrenergic receptor. The drug candidate development is based on water free Eyesol technology. 

Betaliq overview

Betaliq is a biotech company that focuses on the development of ophthalmic beta-blockers. The company is headquartered in Tampa, Florida, the US

For a complete picture of Nebivolol’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.